Cingulate Strengthens Board Compensation with Long-term Stock Options Grant

Rhea-AI Filing Summary

Director Jeffrey S. Ervin of Cingulate has been granted 15,000 stock options on June 20, 2025. The options have the following key terms:

• Exercise price set at $4.14 per share
• Expiration date of June 20, 2035 (10-year term)
• Vesting occurs at the earlier of:
  • One-year anniversary of grant date
  • Date of Cingulate's 2026 annual stockholder meeting

This Form 4 filing represents a standard director compensation grant, with the options providing Ervin the right to purchase common stock at the specified strike price. The grant aligns the director's interests with shareholders through long-term equity incentives.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ervin Jeffrey S

(Last) (First) (Middle)

1901 W. 47TH PLACE

(Street)

KANSAS CITY KS 66205

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to Buy)	$4.14	06/20/2025		A		15,000		(1)	06/20/2035	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders.

	/s/ Shane J. Schaffer, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Jeffrey Ervin receive from CINGW on June 20, 2025?

Jeffrey Ervin received 15,000 stock options with an exercise price of $4.14 per share. These options were granted on June 20, 2025, and will expire on June 20, 2035.

When do Jeffrey Ervin's CINGW stock options vest?

The stock options vest on the earlier of two conditions: (1) the one-year anniversary of the grant date (June 20, 2026) or (2) the date of Cingulate Inc.'s 2026 annual meeting of stockholders.

What is Jeffrey Ervin's role at CINGW?

According to the Form 4 filing, Jeffrey Ervin serves as a Director of Cingulate Inc. (CINGW). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What was the total value of stock options granted to Jeffrey Ervin in this Form 4 filing?

The Form 4 shows that Jeffrey Ervin received 15,000 stock options with a listed price of $0 (grant price). These options have an exercise price of $4.14 per share, meaning he would need to pay $4.14 per share to exercise them in the future.

Who signed this Form 4 filing for CINGW?

The Form 4 was signed by Shane J. Schaffer as Attorney-in-Fact for Jeffrey Ervin on June 23, 2025, three days after the transaction date.